SCHEMBL20695459

SCHEMBL20695459

Cc1ccc(-c2ccc(C(=O)N3CC4(CCC(=O)N4)C3)cc2)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FASN P49327 3/20 0.43
▸ PKM P14618 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ KDM1A O60341 6/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PDE5A O76074 1/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ PDE1A P54750 1/20 0.38
▸ PDE1B Q01064 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ PDE7A Q13946 1/20 0.38
▸ PDE1C Q14123 1/20 0.38
▸ PDE3A Q14432 1/20 0.38
▸ PDE7B Q9NP56 1/20 0.38
▸ MGLL Q99685 2/20 0.38
▸ PDCD1LG2 Q9BQ51 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20695373 0.92 PKM (0.41) FASNPKMGAAKDM1AMEN1
SCHEMBL20695365 0.89 FASN (0.44) FASNGAALMNAMGLL
SCHEMBL20695189 0.89 PKM (0.43) PKMGAAKDM1AMEN1LMNA
SCHEMBL20695449 0.87 PKM (0.43) PKMGAAKDM1AMEN1LMNA
SCHEMBL20695363 0.87 FASN (0.60) FASNMEN1KMT2APDE3AMGLL
SCHEMBL20695139 0.85 FASN (0.40) FASNPDE4BMGLLPDCD1LG2CD274
SCHEMBL20695263 0.85 FASN (0.43) FASNKDM1AMEN1KMT2AMGLL
SCHEMBL20695453 0.83 FASN (0.45) FASNGAALMNAPDE5APDE4A
SCHEMBL20695199 0.82 PKM (0.42) PKMGAAKDM1AMEN1LMNA
SCHEMBL20695153 0.81 SLC6A7 (0.42) GAAMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10610520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-04-07 — — US disclosed
US-20190125728-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-02 — — US disclosed
US-20190125728-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-02 — — US disclosed
EP-3438109-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-02-06 — — EP disclosed
EP-3438109-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-02-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125728-A1 HETEROCYCLIC COMPOUND MAG, HTT, ACHE FASN 3889/4885PKM 2129/4885GAA 477/4885
US-10610520-B2 Heterocyclic compound MAG, HTT, ACHE FASN 3889/4885PKM 2129/4885GAA 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback